SECsense Logo

BioCryst Pharmaceuticals 8-K Report: Key Corporate Developments Revealed

$BCRX
Form 8-K
Filed on: 2025-01-13
Source
BioCryst Pharmaceuticals 8-K Report: Key Corporate Developments Revealed

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Entity Identification:
  • Company Name: BioCryst Pharmaceuticals, Inc.
  • CIK Number: 0000882796
  • IRS Employer Identification Number: 62-1413174
  • Address: 4505 Emperor Blvd. Suite 200, Durham, NC 27703
  • Phone Number: (919) 859-1302
  1. Filing Information:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: January 13, 2025
  1. Trading Information:
  • Stock Symbol: BCRX
  • Exchange: NASDAQ
  1. Financial Reporting Context:
  • Report Date: The report is effective as of January 13, 2025.
  • Currency: The financial measures are reported in U.S. Dollars (USD).
  1. Units of Measurement:
  • Financial measures are presented in USD and shares.
  1. Regulatory Context:
  • The document references XBRL (eXtensible Business Reporting Language), which is used for tagging financial statements to facilitate data sharing and analysis.

Insights:

  • The filing indicates a corporate event or decision that could impact investors or stakeholders, as indicated by the 8-K filing, which is typically used to disclose significant events.
  • The identification of the company and its associated identifiers suggests that it is a publicly traded entity, which is pertinent for investors who may be analyzing stock performance or company stability.
  • The specific reporting date and currency suggest a focus on recent developments as of early 2025, which may be relevant for trend analysis or forecasting.

This information provides a snapshot of BioCryst Pharmaceuticals' regulatory filing, which is crucial for understanding its current corporate situation and informing investment decisions.